Novavax reports Q3 2026 results and raises full-year adjusted revenue guidance
FROM THE WIRE · PRNEWSWIRE.COM
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point In October, Novavax earned a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe higher revenue guidance and a $125 million milestone are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novavax reports $68 million revenue in the third quarter of 2026.
- 02Adjusted full-year 2026 revenue guidance rises by $145 million to $400 million at the midpoint.
- 03Novavax earned a $125 million milestone after Sanofi launched a European Phase 3 trial.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets